| abstract |
REFERS TO AN ANTIGEN-BINDING THERAPEUTIC PROTEIN THAT RECOGNIZES AN EPITOPE OF BETA-AMYLOID PEPTIDE, CONTAINING BETA-AMYELOID REMAINS 28-35, CHARACTERIZED BY BEING AN ANTIBODY OR FRAGMENT OF THE MYBODY / OTHER DERIVATIVES WHICH INCLUDES THE CDR OR A VARIANT OF THE SAME SUCH AS CDRH1 (SEQ ID NO: 1), CDRH2 (SEQ ID NO: 2), AMONG OTHERS; IN WHICH THE HUMAN RECEPTOR HEAVY CHAIN STRUCTURE IS DERIVED FROM IGHV1-24 (SEQ ID NO: 13) TOGETHER WITH A STRUCTURE 4, WHOSE SEQUENCE OF STRUCTURE 4 IS THE ONE THAT ENCODES THE HUMAN MINIGEN JH4 (KABAT) (SEQ NO : 15) AND IN WHICH THE COMPLETE SEQUENCE OF THE CDR3 OF THE HEAVY CHAIN IS PROVIDED BY THE DONOR IMMUNOGLOBULIN, IN ADDITION THE STRUCTURE OF THE LIGHT HUMAN RECEPTOR CHAIN IS DERIVED FROM IGKV2-28 (SEQ ID NO: 16) ALONG 4, WHOSE SEQUENCE OF STRUCTURE 4 IS THE ONE THAT CODES THE HUMAN MINIGEN JK-1 (SEQ ID NO: 18). IT ALSO REFERS TO A PREPARATION METHOD FOR A PHARMACEUTICAL COMPOSITION WITH A COMPLEMENT PATH INHIBITOR SUCH AS COMPLEMENT FACTOR H (CFH) OR A SOLUBLE COMPLEMENT FACTOR 1 (SCR1). SAID PROTEIN HAS AFFINITY WITH AMYELOID PEPTIDE, BEING USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND DISEASES THAT AFFECT THE OPTIC NERVE SUCH AS GLAUCOMA |